Categories: Clinical TrialNews

Angle PLC Announces Posting of 2023 Annual Report & Notice of the AGM

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

GUILDFORD, SURREY / ACCESSWIRE / June 18, 2024 / ANGLE plc (“the Company”) (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report and Financial Statements for the year ended 31 December 2023, and the Notice of Annual General Meeting within it, have been posted to shareholders, and are available on the Company’s website.

The Annual General Meeting will now be held at 12:00 pm on Thursday 11 July 2024 at the Surrey Technology Centre, Surrey Research Park, Guildford, Surrey GU2 7YG. The Board is looking forward to welcoming shareholders in person and will provide a business update after the formalities of the meeting are concluded.

For further information:

ANGLE plc

+44 (0) 1483 343434

Andrew Newland, Chief Executive
Ian Griffiths, Finance Director

Berenberg (NOMAD and Broker)
Toby Flaux, Ciaran Walsh, Milo Bonser

+44 (0) 20 3207 7800

FTI Consulting
Simon Conway, Ciara Martin
Matthew Ventimiglia (US)

+44 (0) 203 727 1000
+1 (212) 850 5624

Notes for editors

About ANGLE plc

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE’s FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 system enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

ANGLE’s commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system and associated consumables. The clinical services business is offered through ANGLE’s GCP-compliant laboratories in the UK. Services include custom made assay development and clinical trial testing for pharma.

Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: ANGLE plc

View the original press release on accesswire.com

View the original press release on accesswire.com

Staff

Recent Posts

Healthee Launches Smarter, Simpler, AI-Powered Benefits Platform

NEW YORK, June 25, 2025 /PRNewswire/ -- Healthee is proud to announce that the reimagined…

10 hours ago

Tobin Scientific Hires Graham Long as Chief Commercial Officer

Seasoned life sciences executive joins in key leadership role to support next phase of growth…

10 hours ago

Fortify Children’s Health Uses Oracle Health Data Intelligence to Enhance Pediatric Care Across Its Clinical Network

Virginia-based pediatric care network gains more complete picture of a child's health history, supports early…

10 hours ago

Elfie raises $12m to expand access to free digital therapeutics for all diseases

NEW YORK, June 25, 2025 /PRNewswire/ -- Elfie, the free digital health super-app that rewards people…

10 hours ago